Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
weaker decrease » greater decrease (Expand Search), teer decrease (Expand Search), water decreases (Expand Search)
decrease risks » increased risks (Expand Search), disease risks (Expand Search), decrease rice (Expand Search)
mean decrease » a decrease (Expand Search)
Showing 61 - 80 results of 23,123 for search '(( significantly ((weaker decrease) OR (mean decrease)) ) OR ( significant decrease risks ))', query time: 0.96s Refine Results
  1. 61
    Bias risk assessments for each RCS study.

    Bias risk assessments for each RCS study. by Xin Liu (43569)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    Forest plots illustrate the mean difference in creatinine level with subgroup analysis based on patients’ age.

    Forest plots illustrate the mean difference in creatinine level with subgroup analysis based on patients’ age. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    The difference in mean score for the five scales of the RISE-Q for breakfast and main meal among study participants (n = 835).

    The difference in mean score for the five scales of the RISE-Q for breakfast and main meal among study participants (n = 835). by Leila Cheikh Ismail (3152526)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 64
    SLE decreases risk for hormonal cancers.

    SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

    Published 2021
    “…(a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). …”
    Save to List
    Saved in:
  5. 65
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and post-test (<i>n</i> = 900). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 66
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 67
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 70
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by gender (<i>n</i> = 662).

    Mean scores compared with paired-samples <i>t</i>-test (and related effect sizes) at pre- and follow-up by gender (<i>n</i> = 662). by Maria Anna Donati (6735548)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: